PARP1 and breast cancer: Some PARP inhibitors, including olaparib, act as PARP1–DNA traps at the sites off single-strand breaks, and prevent the repair of (and enhance) the generation of the double-strand breaks, which are particularly detrimental for breast cancer 1/2 (BRCA1/2)-deficient tumors [15].